Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC

NCT02039336

Last updated date
Study Location
The Netherlands Cancer Institute
Amsterdam, , 1066CX, Netherlands
Contact
0031205122446

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

0031205122446

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Colorectal Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histological or cytological proof of advanced non-small cell lung cancer

- Written documentation of KRAS (exon 2, 3 or 4) mutation

- At least 18 years of age or older

- Able and willing to give written informed consent

- WHO performance status of 0 or 1

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Symptomatic or untreated leptomeningeal disease


- Symptomatic brain metastasis


- Impairment of gastrointestinal function


- Uncontrolled infectious disease


- Left ventricular ejection fraction < 50%


- Retinal degenerative disease or with history of uveitis, retinal vein occlusion or
retinal detachment


Other protocol-defined inclusion/exclusion criteria may apply

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Colorectal CancerPhase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
NCT00522665
  1. Chicago, Illinois
  2. Galesburg, Illinois
  3. Bloomington, Indiana
  4. Evansville, Indiana
  5. Indianapolis, Indiana
  6. Indianapolis, Indiana
  7. Indianapolis, Indiana
  8. Indianapolis, Indiana
  9. Lafayette, Indiana
  10. Lafayette, Indiana
  11. Munster, Indiana
  12. New Albany, Indiana
  13. South Bend, Indiana
  14. St. Louis, Missouri
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Colorectal CancerA Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
NCT01490866
  1. Jonesboro, Arkansas
  2. Fort Myers, Florida
  3. Pensacola, Florida
  4. Saint Petersburg, Florida
  5. Gainesville, Georgia
  6. Newburgh, Indiana
  7. Terre Haute, Indiana
  8. Grand Rapids, Michigan
  9. Omaha, Nebraska
  10. Summit, New Jersey
  11. Nashville, Tennessee
  12. Dallas, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Colorectal CancerFOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer
NCT00323011
  1. Los Angeles, California
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
Official Title  ICMJE Phase I/II Study With the Combination of Dacomitinib and PD-0325901 in Metastatic KRAS Mutation Positive Non-small Cell Lung Cancer
Brief Summary This is a phase I/II multi-center open-label proof of concept study, consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of dacomitinib plus PD-0325901 in patients with advanced KRAS mutant (KRASm) non-small cell lung cancer (NSCLC). Part B is designed to perform a randomized comparison of the combination of dacomitinib and PD-0325901 versus standard of care therapy in patients with advanced KRASm NSCLC. It is hypothesized that with this combination strategy the progression free survival of patients with KRASm NSCLC will be doubled.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Colorectal Cancer
Intervention  ICMJE
  • Drug: Dacomitinib
  • Drug: PD-0325901
  • Drug: Docetaxel
Study Arms  ICMJE Experimental: Dacomitinib + PD-0325901
Dacomitinib: oral tablets PD-0325901: oral capsules
Interventions:
  • Drug: Dacomitinib
  • Drug: PD-0325901
  • Drug: Docetaxel
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: January 15, 2014)
35
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2019
Estimated Primary Completion Date December 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histological or cytological proof of advanced non-small cell lung cancer
  • Written documentation of KRAS (exon 2, 3 or 4) mutation
  • At least 18 years of age or older
  • Able and willing to give written informed consent
  • WHO performance status of 0 or 1

Exclusion Criteria:

  • Symptomatic or untreated leptomeningeal disease
  • Symptomatic brain metastasis
  • Impairment of gastrointestinal function
  • Uncontrolled infectious disease
  • Left ventricular ejection fraction < 50%
  • Retinal degenerative disease or with history of uveitis, retinal vein occlusion or retinal detachment

Other protocol-defined inclusion/exclusion criteria may apply

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Netherlands
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02039336
Other Study ID Numbers  ICMJE NL45985.031.13
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party The Netherlands Cancer Institute
Study Sponsor  ICMJE The Netherlands Cancer Institute
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Director:f opdam, MD, PhDThe Netherlands Cancer Institute
Principal Investigator:FALM Eskens, PhDErasmus Medical Centre Cancer Institute
Principal Investigator:MPJK Lolkema, PhDUMC Utrecht
PRS Account The Netherlands Cancer Institute
Verification Date August 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP